Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

被引：73

作者：

Baldwin, Susan L. ^{[1
]}

Bertholet, Sylvie ^{[1
]}

Kahn, Maria ^{[1
]}

Zharkikh, Irina ^{[1
]}

Ireton, Gregory C. ^{[1
]}

Vedvick, Thomas S. ^{[1
]}

Reed, Steven G. ^{[1
]}

Coler, Rhea N. ^{[1
]}

机构：

[1] Infect Dis Res Inst, Seattle, WA 98104 USA

来源：

VACCINE | 2009年 / 27卷 / 23期

关键词：

Mycobacterium tuberculosis; Subunit vaccine; TLR agonists; MYCOBACTERIUM-TUBERCULOSIS INFECTION; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; LEISHMANIA-MAJOR; LANGERHANS CELLS; GUINEA-PIG; MICE; ALPHA;

D O I：

10.1016/j.vaccine.2009.03.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (11383), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3063 / 3071

页数：9

共 45 条

[31] Who puts the tubercle in tuberculosis? [J].